NRC FORM 591M PART 1
(10-2003) 10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Clark Memorial Hospital **1220 Missouri Avenue** **Jeffersonville, IN 47130** REPORT NUMBER(S) **2010-001**	**U.S. Nuclear Regulatory Commission** **Region III** **2443 Warrenville Road** **Suite 210** **Lisle, Illinois 60532-4351**

3. DOCKET NUMBER(S)	4. LICENSEE NUMBER(S)	5. DATE(S) OF INSPECTION
030-01658	**13-12367-01**	**June 29, 2010**

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

[X] 1. Based on the inspection findings, no violations were identified.

[ ] 2. Previous violation(s) closed.

[ ] 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

[ ] 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	**S. J. Mulay**		**07/08/10**

NRC FORM 591M PART 1 (10-2003)

NRC FORM 591M PART 3
(10-2003) 10 CFR 2.201

Docket File Information

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT
AND COMPLIANCE INSPECTION

1. LICENSEE	2. NRC/REGIONAL OFFICE
Clark Memorial Hospital REPORT NUMBER(S) 2010/001	Region III 2443 Warrenville Road, Suite 210 Lisle, IL 60532

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-01658	13-12367-01	June 29, 2010

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87132	03.01-03.07

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
2120	3	Kevin Serey, M.D., RSO	812-283-2313

[X] Main Office Inspection — Next Inspection Date: June 2013

[ ] Field Office

[ ] Temporary Job Site Inspection

PROGRAM SCOPE

This active medical program uses byproduct material as authorized in 10 CFR 35.100-400. The licensee employs three full-time technologists in nuclear medicine. Approximately 400 diagnostic procedures are performed monthly. In addition, approximately one hyperthyroid (HTT) treatment is done monthly and four ablation doses are administered annually both in capsule form. The licensee's manual brachytherapy program consists of about three ultrasound guided iodine-125 prostate implants annually. Iodine-125 seeds for implant are delivered to the nuclear medicine department for processing and storage pending implant by an outside radiation oncology group at the licensee's facility.

Performance Observations

Written directives were reviewed for the radioiodine and brachytherapy programs with no regulatory issues noted. Actual patient treatments were not scheduled on the day of inspection. The inspector observed two diagnostic patient injections, dose calibrator constancy checks, and area and package survey techniques and reviewed various QMP scenarios with available staff members. Side by-side survey instrument readings indicated sufficient comparison with NRC instrument. Security of licensed material was adequately implemented and maintained.

Independent measurements of use and storage areas did not indicate readings above expected. Personal dosimetry was available and worn by appropriate staff. Dosimetry records reviewed for the period 2009 and 2010 did not approach 10 CFR 20 limits.

NOTE: On 6/14/10, the licensee began using an area in the hospital for diagnostic cardiac administrations and imaging which was separate from the nuclear medicine department. The licensee notified the NRC Regional Office of this area in a letter dated 6/7/2010 (received on 6/25/10). 10 CFR 35.14 (b)(5) states, in part, that the licensee shall notify the NRC within 30 days when a licensee has added or changed areas of use identified in the license where byproduct material is used in accordance with 10 CFR 35.100 or 35.200. Since the licensee had been performing only 10 CFR 35.200 procedures for this area, the notification is considered timely and is being treated as an amendment request currently under review by the Materials Licensing Branch.

1 of 5